Conner Bardine

Conner Bardine

Auto-generated profile, based on publicly available information

Conner Bardine

Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California 94143, United States

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2021 in ACS Central Science
Verified
Journal Article
Open access
NZNing Zhao
Ning Zhao
CBConner Bardine
Conner Bardine
ALAndré Luiz Lourenço
André Luiz Lourenço
YWYung-Hua Wang
Yung-Hua Wang
YHYangjie Huang
Yangjie Huang
CCCharles Craik
Charles Craik
The biology of human granzymes remains enigmatic in part due to our inability to probe their functions outside of in vitro assays or animal models with divergent granzyme species. We hypothesize that the biology of human granzymes could be better elaborated with a translational imaging technology to reveal the contexts in which granzymes are secreted and biochemically active in vivo. Here, we advance toward this goal by engineering a Granzyme targeting Restricted Interaction Peptide specific to family member B (GRIP B) to measure secreted granzyme B (GZMB) biochemistry with positron emission tomography. A proteolytic cleavage of 64Cu-labeled GRIP B liberates a radiolabeled form of Temporin L, which sequesters the radioisotope by binding to adjacent phospholipid bilayers. Thus, at extended time points postinjection (i.e., hours, not seconds), tissue biodistribution of the radioisotope in vivo reflects relative units of the GZMB activity. As a proof of concept, we show in three syngeneic mouse cancer models that 64Cu-GRIP B detects GZMB from T cells activated with immune checkpoint inhibitors (CPI). Remarkably, the radiotracer detects the proteolysis within tumors but also in lymphoid tissue, where immune cells are activated by a systemic CPI. Control experiments with an uncleavable analogue of 64Cu-GRIP B and tumor imaging studies in germline GZMB knockout mice were applied to show that 64Cu-GRIP B is specific for GZMB proteolysis. Furthermore, we explored a potential noncytotoxic function for GZMB by applying 64Cu-GRIP B to a model of pulmonary inflammation. In summary, we demonstrate that granzyme biochemistry can be assessed in vivo using an imaging modality that can be scaled vertically into human subjects.

23 November 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HOHenry R. O’donnell
Henry R. O’donnell
TTTia A. Tummino
Tia A. Tummino
CBConner Bardine
Conner Bardine
CCCharles Craik
Charles Craik
BSBrian K. Shoichet
Brian K. Shoichet

12 August 2022 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
LSLucianna H. Santos
Lucianna H. Santos
TKThales Kronenberger
Thales Kronenberger
RARenata G. Almeida
Renata G. Almeida
ESElany B. Silva
Elany B. Silva
RRRafael E. O. Rocha
Rafael E. O. Rocha
RFRafaela Salgado Ferreira
Rafaela Salgado Ferreira

6 July 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
EFElissa A. Fink
Elissa A. Fink
CBConner Bardine
Conner Bardine
SGStefan Gahbauer
Stefan Gahbauer
ISIsha Singh
Isha Singh
KWKris White
Kris White
CCCharles Craik
Charles Craik
Antiviral therapeutics to treat SARS-CoV-2 are much desired for the on-going pandemic. A well-precedented viral enzyme is the main protease (MPro), which is now targeted by an approved drug and by several investigational drugs. With the inevitable liabilities of these new drugs, and facing viral resistance, there remains a call for new chemical scaffolds against MPro. We virtually docked 1.2 billion non-covalent and a new library of 6.5 million electrophilic molecules against the enzyme structure. From these, 29 non-covalent and 11 covalent inhibitors were identified in 37 series, the most potent having an IC 50 of 29 μM and 20 μM, respectively. Several series were optimized, resulting in inhibitors active in the low micromolar range. Subsequent crystallography confirmed the docking predicted binding modes and may template further optimization. Together, these compounds reveal new chemotypes to aid in further discovery of MPro inhibitors for SARS-CoV-2 and other future coronaviruses.

5 January 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
LSLucianna H. Santos
Lucianna H. Santos
TKThales Kronenberger
Thales Kronenberger
RARenata G. Almeida
Renata G. Almeida
ESElany B. Silva
Elany B. Silva
RRRafael E. O. Rocha
Rafael E. O. Rocha
RFRafaela Salgado Ferreira
Rafaela Salgado Ferreira
The worldwide COVID-19 pandemic caused by the coronavirus SARS-CoV-2 urgently demands novel direct antiviral treatments. The main protease (Mpro) and papain-like protease (PLpro) are attractive drug targets among coronaviruses due to their essential role in processing the polyproteins translated from the viral RNA. In the present work, we virtually screened 688 naphthoquinoidal compounds and derivatives against Mpro of SARS-CoV-2. Twenty-four derivatives were selected and evaluated in biochemical assays against Mpro using a novel fluorogenic substrate. In parallel, these compounds were also assayed with SARS-CoV-2 PLpro. Four compounds inhibited Mpro with half-maximal inhibitory concentration (IC 50 ) values between 0.41 µM and 66 µM. In addition, eight compounds inhibited PLpro with IC 50 ranging from 1.7 µM to 46 µM. Molecular dynamics simulations suggest stable binding modes for Mpro inhibitors with frequent interactions with residues in the S1 and S2 pockets of the active site. For two PLpro inhibitors, interactions occur in the S3 and S4 pockets. In summary, our structure-based computational and biochemical approach identified novel naphthoquinonal scaffolds that can be further explored as SARS-CoV-2 antivirals.

18 December 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
BFBryan Fraser
Bryan Fraser
NYNicholas Young
Nicholas Young
BBBrian Bender
Brian Bender
SGStefan Gahbauer
Stefan Gahbauer
OIOlzhas Ilyassov
Olzhas Ilyassov
CACheryl Arrowsmith
Cheryl Arrowsmith
Transmembrane protease, serine -2 (TMPRSS2) is an essential host entry factor in human airways for SARS-CoV-2 and influenza A/B and has presented as a target for antiviral drug development; however, no clinically viable, oral small molecule TMPRSS2 inhibitors have been developed to date. Here we perform two large-scale docking campaigns to identify covalent and noncovalent TMPRSS2 small molecule inhibitors from a homology model and crystal structure. We establish a pipeline to rapidly screen TMPRSS2 inhibitors, then interrogate the potency, specificity and biophysical properties of covalent and noncovalent inhibition using enzyme kinetics on synthetic peptide and protein substrates and differential scanning fluorimetry. Furthermore, we established a readily crystallizable form of TMPRSS2 protein that produced high resolution crystal structures with nafamostat, ‘157, and 6-amidino-2-naphthol. A novel noncovalent inhibitor scaffold is biochemically and biophysically validated as a potential avenue to develop TMPRSS2-selective inhibitors.